Dr. Peter Beitsch on Pertuzumab in the Luminal Subtype of HER2-Positive Breast Cancer

December 22, 2015
Peter Beitsch, MD

Peter Beitsch, MD, breast surgeon, Medical City Dallas Hospital, discusses a triplet of chemotherapy, trastuzumab, and pertuzumab in the adjuvant and neoadjuvant settings.

Peter Beitsch, MD, breast surgeon, Medical City Dallas Hospital, discusses a triplet of chemotherapy, trastuzumab, and pertuzumab in the adjuvant and neoadjuvant settings. Beitsch argues that pertuzumab should be included in the triplet due to its prolonging survival in patients with HER2-positive breast cancer that have the 80-gene Luminal subtype.